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Background: Tumor metastasis is an essential cause of the poor prognosis of colon cancer. DC-SIGNR is a C-type
lectin that is frequently found on human liver sinusoidal endothelial cells. LSECtin, which is a homologue of DC-
SIGNR, has been demonstrated to participate in colon cancer liver metastasis. Due to the similarities in the
expression pattern and structure of the two proteins, we speculated that DC-SIGNR could also be involved in this
process.
Methods: Colon cancer cells were treated with the DC-SIGNR protein or control IgG, after which cell migration,
invasion, and morphology were assayed. Xenograft mouse models were used to determine the role of DC-SIGNR in
colon cancer liver metastasis in vivo. In addition, a human gene expression array was used to detect differential
gene expression in colon cancer cells stimulated with the DC-SIGNR protein. The serum level of DC-SIGNR was
examined in colon cancer patients by ELISA, and the significance of DC-SIGNR was determined.
Results: In our research, we investigated whether DC-SIGNR promotes colon cancer cell adhesion, migration, and
invasion. Knocking down mouse DC-SIGNR decreased the liver metastatic potency of colon cancer cells and
increased survival time. Expressing human DC-SIGNR enhanced colon cancer liver metastasis. Furthermore, DC-
SIGNR conferred metastatic capability on cancer cells by upregulating various metallothionein isoforms. To validate
the above results, we also found that the serum DC-SIGNR level was statistically higher in colon cancer patients
with liver metastasis compared with those without metastasis.
Conclusions: These results imply that DC-SIGNR may promote colon carcinoma hepatic metastasis and could serve
as a promising therapeutic target for anticancer treatment.
Keywords: DC-SIGNR, Colon cancer liver metastasis, MetallothioneinsBackground
Tumor metastasis, the main feature of malignant tu-
mors, is often considered to be the most lethal property
of cancer cells [1]. The process of tumor metastasis is
complex, continuous, and multifactorial. Tissue-specific
interactions play a critical role in the initiation of tumor
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tive of the organ microenvironment, both the vessel
diameter of capillary walls and the structural compos-
ition of blood vessels can affect tumour cell infiltration
[4, 5]. The capillaries of the liver and lymph nodes are
found to be lined with fenestrated endothelial cells and
are thus more permissive to the recruitment of tumour
cells. Furthermore, some specific ligands on the endo-
thelial cells are also involved in tumor metastasis. At the
same time, tumor cells can optimize their motility de-
pending on the environment of the surrounding tissues
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metastasis [6].
DC-SIGNR, dendritic cell-specific intercellular adhe-
sion molecule-grabbing nonintegrin-related protein, is a
C-type II integral membrane protein. It is predominantly
found on the sinusoidal endothelial cells in the liver and
lymph nodes as well as in the placental endothelium [7].
Generally, the importance of DC-SIGNR is due to its
role as a cell-adhesion receptor that has high affinity for
ICAM-2, ICAM-3, Lewisa, Lewisb, and Lewisy [8]. DC-
SIGNR is also involved in the innate immune system
and recognizes diverse pathogens, ranging from viruses
to parasites, that have a tremendous impact on public
health. It has been reported to play an important role in
various pathophysiological conditions, such as hepatitis
C, HIV, and severe acute respiratory syndrome [9–11].
LSECtin belongs to a subfamily that includes DC-
SIGNR, DC-SIGN, and CD23 and is also found on the
liver sinusoidal endothelial cells. It has been demon-
strated that LSECtin is a crucial regulator of colon can-
cer liver metastasis [12]. The serum LSECtin level in
patients with colon cancer liver metastasis was higher
than that in patients without metastasis, and LSECtin in-
creased the expression of c-Met in colon cancer cells.
Recently, our laboratory has reported that the level of
serum DC-SIGNR in colon cancer patients was higher
than in healthy volunteers [13]. DC-SIGNR may be a
significant biomarker that could be used for the diagno-
sis of early stage colon cancer. Furthermore, many other
C-type lectins have also been demonstrated to be in-
volved in tumour metastasis. Christopher R. Parish et al.
found that endothelial-derived P-selectin was as import-
ant as platelet-derived P-selectin in aggravating lung me-
tastases and participated in liver metastasis [14]. Sayeda
Yasmin-Karim emphasized that the interaction of E-
selectin and the E-selectin ligand mediated the rolling
and adhesion of prostate cancer cells on the endothelial
surface through the RAS-ERK-MAP kinase pathway
[15]. The mannose receptor promoted colon carcinoma
cell interaction with the liver sinusoidal endothelium
and contributed to colon cancer hepatic metastasis,
which was induced by interleukin-1 [16]. Therefore, we
hypothesized that DC-SIGNR could also be associated
with human colon cancer progression.
Metallothioneins are a group of evolutionarily con-
served, low molecular weight, cysteine-rich proteins.
The metallothionein genes are located on chromosome
16 (16q12-22) in humans. There are four primary metal-
lothionein isoforms: MT1, MT2, MT3, and MT4.
Whereas MT1 and MT2 are commonly expressed, MT3
seems to be restricted to the brain, and MT4 is specific-
ally found in certain squamous epithelial tissues. Fur-
thermore, there are eight functional paralogs of MT1
(MT1A, MT1B, MT1E, MT1F, MT1G, MT1H, MT1M,and MT1X) [17]. Metallothioneins, as redox-active pro-
teins, have many functions, including zinc homeostasis,
heavy metal detoxification and metal transfer [18]. They
can facilitate the chemoresistance to some anti-cancer
drugs [19, 20]. In recent years, metallothioneins have
been shown to be related to tumor stage, therapy resist-
ance, poor prognosis, and survival in many cancers [21].
In our study, we aimed to gain insights into the im-
portant biological effect of DC-SIGNR on colon cancer.
We found that colon cancer patients with liver metasta-
sis showed higher levels of DC-SIGNR compared with
patients without metastasis. In addition, DC-SIGNR ex-
pression could be induced on colon cancer cells through
various changes in the tumour microenvironment. Fur-
thermore, DC-SIGNR mediated the upregulation of
metallothioneins. Both in vitro and in vivo experiments
were performed to elucidate the relevance of DC-
SIGNR-mediated tumor metastasis, and the inhibition of
DC-SIGNR activity or of downstream DC-SIGNR-
regulated events could be a therapeutic intervention for
colon cancer formation.
Methods
Cell culture and nude mice
Colon cancer cells LoVo, LS174T and HCT-116 were
used in this research. Cells were cultured in RPMI 1640
medium supplemented with 10% fetal bovine serum and
100 U/ml penicillin and streptomycin (Beyotime, China).
Cells were maintained in a 37 °C incubator with 5% CO2
humidified air. Six-to-eight-week old nude mice were
purchased from Dalian Medical University (Dalian,
China). They were bred and acclimated under specific
pathogen-free conditions. All of the animal studies were
conducted in accordance with the Institutional Animal
Care and Use Committee of Dalian Medical University.
Patients
A total of 81 patients with colon cancer were enrolled in
our study, and all patients were treated in the First or
Second Affiliated Hospital of Dalian Medical University.
None of the patients were immediate relatives. Clinical
information about patients is listed in Additional file 1:
Table S2. The control group consisted of 57 healthy vol-
unteers. These clinical materials for research were ap-
proved by the Research Ethics Committee of Dalian
Medical University.
Plasmid
DC-SIGNR expression plasmid was produced and
depended on cDNA fragment containing the full coding
sequence of DC-SIGNR ((nt)39-1184, AF290887). Two
shRNA sequences for knockdown of mouse DC-SIGNR
were shRNA a: 5′-GCAGACTTCTAAGGCTAAAGG-
3′; shRNA b 5′-GCTCCAGA CTACGACCAAATT-3′.
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which has no significant homology with the target se-
quence. It was 5′-GTTCTCCGAACGTGTCACGT-3′.
All of the plasmids were designed and synthesized by
Shanghai Gene Pharma (Shanghai, China).
Detection of soluble DC-SIGNR in colon cancer patients
The serum levels of DC-SIGNR were measured using a
commercial sandwich enzyme-linked immunosorbent
assay method. The wells of 96-well microplates were
coated with 100 μl of an anti-DC-SIGNR goat polyclonal
antibody (1:1000, Santa Cruz Biotechnology, Inc., USA)
at a final concentration of 0.27 μg/ml as a capture anti-
body and incubated overnight at 4 °C. The plates were
washed three times with phosphate buffered saline (PBS)
containing 0.05% Tween-20 (PBST, pH 7.4), and the
wells were blocked with blocking buffer (5% bovine
serum albumin) at 37 °C for 1 h. The plates were washed
three times with PBST. Then, 100 μl of diluted rhDC-
SIGNR-Fc standard was added to the wells along with
the serum from colon cancer patients and healthy con-
trols. As a negative control, 100 μl of PBS was used.
Each plate was incubated at 37 °C for 2 h. Subsequently,
PBST was used to wash the plates three times, and
100 μl of an anti-DC-SIGNR mouse monoclonal anti-
body (1:1000, R&D Systems, Inc., USA) diluted to a con-
centration of 0.5 μg/ml was added to each well. The
plates were incubated at 37 °C for 1.5 h. After washing,
100 μl of a peroxidase-conjugated goat anti-mouse anti-
body (1:1000, ZSGB-BIO, China) was added, and the
plates were incubated at 37 °C for 1 h. Finally, the plates
were washed three times and incubated with 3, 3′, 5, 5′-
tetramethylbenzidine (TMB, TIANGEN BIOTECH CO,
LTD.) at 37 °C for 0.5 h, and then 2 mol/L H2SO4 was
added to stop the reaction. The optical density (OD) was
measured at a wavelength of 450 nm in a microplate
reader. The quantitative DC-SIGNR concentrations were
determined by comparing the optical density values with
the standard curve (Additional file 2: Figure S5).
Cell adhesion and flow cytometry
The colon cancer cell lines LoVo, LS174T and HCT-116
were treated with a recombinant human DC-SIGNR
protein or control IgG on ice for 3 h. To detect the
interaction between the cells and the protein, the cells
were incubated with an anti-DC-SIGNR mouse mono-
clonal antibody (1:100, R&D Systems, Inc., USA) on ice
for 1 h. The cells were gently washed three times with
PBS. Then, a fluorescein isothiocyanate-conjugated goat
anti-mouse IgG secondary antibody (1:50, ZSGB-BIO,
China) was added, and the cells were incubated on ice
for another 1 h. The cells were then washed and fixed in
4% paraformaldehyde. The adherent cells were measured
the next day using a FACSCalibur instrument (BDBiosciences, USA). For the inhibition assay, the DC-
SIGNR protein (5 μg/ml) was pre-incubated with se-
lected ligands, including EDTA, D-mannose, galactose,
N-acetylglucosamine, and L-fucose.
In vitro migration and invasion assays
Cells were treated with the recombinant DC-SIGNR
protein or with control IgG. The in vitro migration assay
was performed in 24-well plates with Transwell inserts
(6.5 mm in diameter, 8-μm pore size, Corning, USA).
For the invasion assay, the cells were incubated on the
Matrigel-coated membranes of the inserts. The cells
were incubated for 24 h, and then the cells on the upper
membrane, which had not migrated or invaded, were re-
moved using a cotton swab. Subsequently, the cells on
the lower side of the membrane were fixed in methanol
for 15 min and stained with 0.5% crystal violet for
30 min. For the wound healing assay, cell monolayers
were wounded by a sterile pipet tip when the cells were
nearly 100% confluent. The movement of the cells was
photographically monitored at 0 and 24 h after the
wounding. Images were taken at the indicated time
points (Olympus IX71, Japan).
Colony formation assay
LoVo, LS174T, and HCT-116 colon cancer cells were
seeded in six-well plates at a density of 1000 cells per
well. The cells were treated with 5 μg/ml DC-SIGNR
protein or control IgG. After incubating for 14 days at
37 °C in a humidified 5% CO2 atmosphere, visible clones
appeared. The cells were washed with PBS and stained
with 0.5% crystal violet in methanol for 45 min. Colonies
with >50 cells were counted using an optical microscope
(Olympus IX71, Japan).
Injection of plasmid DNA
Naked plasmid DNA was administered to mice in a large
volume via tail vein injection. The volume of the solu-
tion used corresponded to 8% of the body weight of the
mouse, i.e., 1.6–1.8 ml. The injections were completed
within 5–7 s.
Reverse transcription polymerase chain reaction
Total RNA was isolated from liver tissues using TRIzol re-
agent (TaKaRa Bio, Japan). The human DC-SIGNR tran-
script was amplified with the following primers: forward
primer, 5′- TGTCCAAGGTCCCCAGCTCCC-3′, reverse
primer, 5′-GAACTCACCAAATGCAGTCTTCAAATC-
3′. The mouse DC-SIGNR primers were: forward primer,
5′-TGGCAGTCTCCAAAACCCCAAATAC-3′, reverse
primer, 5′-ACGGCGTCATTCCAGTTCCGC-3′. β-actin
was selected as the endogenous control and was amplified
using the following primers: forward primer 5′-
GGCTGTATTCCCCTCCATCG-3′, reverse primer 5′-
Na et al. Journal of Hematology & Oncology  (2017) 10:28 Page 4 of 18CCAGTTGGTAACAATGCCATGT-3′. The PCR ampli-
fication products were distinguished on a 1% agarose
(Pronadisa, Spain) gel containing 0.5 μg/ml Gold View I
and visualized under a UV transilluminator.
Western blot analysis
Proteins from mouse liver tissues and from LoVo,
LS174T and HCT-116 cells were extracted and sepa-
rated on Tris-glycine gels, and western blot analyses
were performed according to standard procedures.
The protein extracts were immunoblotted with a
mouse DC-SIGNR antibody (1:1000, R&D Systems,
Inc., USA), human DC-SIGNR antibody (1:500,
Abcam, USA), metallothionein antibody (1:150, Bio-
synthesis Biotechnology, China), and MMP9 antibody
(1:1000, Elabscience Biotechnology, China). A β-actin
antibody was used as a control.
Establishment of the liver metastatic model
Mice were anaesthetized with pentobarbital sodium
(Sigma, USA) at 45 mg/kg body weight by intrasplenic
injection. A 1-cm incision was made in the left flank,
and the spleen was separated and exteriorized. Then,
5 × 106 LoVo, LS174T or HCT-116 cells were injected
into the spleen. The spleen was returned to the abdom-
inal cavity, and the wound was sutured. When signs of
abdominal distension or locomotive deficit appeared or
a tumor was detected by palpation, the mice were killed,
and their livers and spleens were harvested.
Immunohistochemistry analysis
Tissue slides were deparaffinized, rehydrated and
boiled in citrate buffer. The tissue sections were incu-
bated with primary Ki67 (1:100, Bioworld Technology,
China), CEA (1:100, Bioworld Technology, China),
CK20 (1:100, Bioworld Technology, China) and CK7
(1:100, Proteintech, China) antibodies overnight at 4 °
C. Then, the sections were incubated with an HRP-
conjugated anti-rabbit antibody (1:1000, ZSGB-BIO,
China) for 30 min at 37 °C, stained with DAB, and
counterstained with haematoxylin.
Human gene expression array
LoVo cells were incubated with the recombinant DC-
SIGNR protein or control IgG for 4 h. Total RNA was
isolated and analyzed on an Affymetrix GeneChip Pri-
meViewTM Human Gene Expression Array (Affymetrix,
Santa Clara, CA). On this chip, 530,000 probe sets rep-
resent more than 20,000 genes, which are completely an-
notated by the RefSeq RNA database.
Quantitative real-time PCR validation
Quantitative real-time PCR was used to validate the
changes in expression of metallothioneins and MMP9 incolon cancer cells. cDNA was synthesized using a Prime-
Script II 1st Strand cDNA Synthesis Kit (TaKaRa Bio,
Japan). All PCR reactions were performed at least in
triplicate, and the results were analysed on a Thermal
Cycler Dice Real-Time System (TaKaRa Bio, Japan) using
SYBR Premix Ex TaqTM PCR master mix (TaKaRa Bio,
Japan). GAPDH was selected as the endogenous control.
The primer pairs used for PCR are presented in Add-
itional file 3: Table S3. The fold change of each gene was
calculated using the delta-delta CT method.
Statistical analysis
The data were presented as the mean ± SD as indi-
cated. Comparisons between two groups were
assessed using an unpaired two-tailed t test. A one-
way ANOVA with Tukey’s Multiple Test were used
for comparisons between multiple groups. The non-
parametric Mann-Whiney U test was employed to
analyse the association of DC-SIGNR levels with vari-
ous clinicopathologic characteristics. The survival ana-
lysis was performed using the log-rank (Mantel-Cox)
test. For all tests, a P value of <0.05 was considered
significant. All results were reproduced across tripli-
cate experiments, and the statistical analyses were
carried out using GraphPad Prism (GraphPad Soft-
ware, Inc., USA).
Results
Recombinant DC-SIGNR protein adheres to LoVo, LS174T,
and HCT-116 cells
Because DC-SIGNR acts as an adhesion receptor, we first
wondered whether DC-SIGNR was associated with the
metastatic potential of colon cancer cells. We examined the
capability of the DC-SIGNR protein to bind to colon cancer
cells. The DC-SIGNR recombinant protein (R&D Systems,
Inc., USA) encodes the extracellular domain (Ser 78-Glu
399) of human DC-SIGNR and is stably expressed in
mouse myeloma cell line (derived from NS0 cell, the non-
Ig secreting and non-light chain-synthesizing cell line) by
Gene engineering technique. By a series of extraction and
purification process, the Fc-DC-SIGNR Chimera is gener-
ated. It has been used in many applications [13, 22]. We
verified the expression of human Fc-DC-SIGNR by West-
ern Blot analysis (Fig. 1a). We used HEK-293Tcells infected
with a lentivirus expressing DC-SIGNR as a positive control
[23]. The expression of DC-SIGNR was detected using a
DC-SIGNR primary antibody (1:2000, Abcam, USA) and a
peroxidase-conjugated anti-rabbit IgG secondary antibody
(1:4000, ZSGB-BIO, China). The predicted molecular
weight for the antibody is 45 kDa. In addition, the predicted
molecular weight of our recombinant human DC-SIGNR
chimera protein is 61.4 kDa, based on its migration on an
SDS-PAGE gel. We then treated three colon cancer cell
lines, LoVo, LS174T, and HCT-116, with human DC-
Fig. 1 DC-SIGNR regulates colon cancer cell adhesion. a The DC-SIGNR protein was detected by Western Blot. b LoVo, LS174T, and HCT-116 cells were
incubated with the recombinant DC-SIGNR protein on ice for 3 h. The adhesion complexes were detected by an antibody against DC-SIGNR and
a FITC-conjugated goat anti-mouse IgG secondary antibody and analysed by flow cytometry. The adhesive ratio of the three colon cancer cell
lines was 72.30% for the LoVo cells, 82.84% for the LS174T cells and 70.47% for the HCT-116 cells. c, d LoVo cells were treated with different
concentrations of the DC-SIGNR protein (1, 2 and 5 μg/ml). For the inhibition assay, the DC-SIGNR (5 μg/ml) protein was pre-incubated with EDTA,
galactose, D-mannose, N-acetylglucosamine, or L-fucose. The binding of DC-SIGNR to LoVo cells was dose-dependent, and the interaction could
be inhibited by EDTA and monosaccharides. ***P < 0.001. The error bars in all graphs represent SD, and each experiment was repeated
three times
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mouse IgG isotype control was used to block any nonspe-
cific binding sites of the anti-DC-SIGNR mouse primary
antibody. The results indicated that the DC-SIGNR
protein bound strongly to these three cell types. The
respective adhesive ratios were 72.30% for LoVo
cells, 82.84% for LS174T cells, and 70.47% for HCT-
116 cells (Fig. 1b). Notably, the binding of the DC-
SIGNR protein to LoVo cells occurred in a dose-
dependent manner (Fig. 1c). DC-SIGNR is a C-type
II transmembrane lectin containing a calcium-
dependent carbohydrate recognition domain (CRD)
and a second site analogous to that identified in
mannose-binding protein [24]. In addition, DC-
SIGNR selectively binds some monosaccharides in a
Ca2+-dependent manner, suggesting that the binding
sites are analogous to those observed in other C-
type lectin CRDs [7, 25]. Therefore, we sought to
determine whether DC-SIGNR could recognize li-
gands on colon cancer cells through calcium- and
mannose-dependent binding. The results showed that
the binding of DC-SIGNR to colon cancer cells re-
quired the presence of Ca2+, as this binding was
inhibited by the addition of a Ca2+ binding chelator
(EDTA) (Fig. 1d). The interaction could also be
blocked by the addition of some monosaccharides,
namely, D-mannose, galactose, N-acetylglucosamine,
and L-fucose (Fig. 1d). Thus, these data indicate that
the interaction between DC-SIGNR and colon cancercells may be calcium-dependent and that DC-SIGNR
may bind to colon cancer cells through a protein-
glycan interaction.
DC-SIGNR positively regulates colon cancer cell migration
and invasion independent of cellular proliferation
The other two main characteristics of metastatic cancer
cells are migration and their ability to degrade physical
barriers, such as extracellular matrix components, to in-
vade new tissues. To assess the effect of DC-SIGNR on
cell motility and invasion, we used Transwell inserts as
described above. We found that the DC-SIGNR protein
markedly enhanced the migration of the three types of
colon cancer cells and that more cells invaded into the
MatrigelTM in the DC-SIGNR protein-treated group
than in the untreated group (Fig. 2a, b). To further valid-
ate these results, we also observed the cell morphology
and performed a wound healing assay. By comparing the
morphology of the cells described above under a light
microscope, we observed that DC-SIGNR could induce
scattering of the colon cancer cells and change the
morphology of the cells from epithelial-like to a more
elongated cell shape (Fig. 2c). This is typified by a mor-
phologic polarization consisting of the formation of pro-
trusions in the process of cell migration [26, 27].
Additionally, in a wound-healing assay, the cancer cells
treated with the DC-SIGNR protein were able to heal
the inflicted wound significantly faster than the un-
treated control cells (Fig. 2d, e). Taken together, these
Fig. 2 DC-SIGNR promotes colon cancer cell migration and invasion in vitro. a Crystal violet staining showed that DC-SIGNR positively promoted the
migration and invasion ability of the three colon cancer cell lines. Scale bars, 100 μm. b The in vitro migration and invasion promoting activities of
colon cancer cells treated with the DC-SIGNR protein or control IgG were measured by determining the number of cells that passed through the
Transwell membrane. c Morphology micrographs of the three types of colon cancer cells treated with the DC-SIGNR protein or control IgG for 24 h.
The DC-SIGNR protein induced scattering of the three types of colon cancer cells. Scale bars, 50 μm. d Pictures of the wound healing assay in LoVo
cells incubated with the DC-SIGNR protein or control IgG at 24 h after the cells were scratched. The LoVo cells treated with the DC-SIGNR protein
migrated more quickly than those treated with control IgG. Scale bars, 100 μm. e The relative cell migrations of the three colon cancer cell lines at 24 h
after the cells were scratched are shown in this panel. The error bars in all graphs represent SD, and the results were quantified from three experiments
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invasion abilities on colon cancer cells.
To confirm whether the results of the in vitro mi-
gration and invasion assays were due to differences in
cellular proliferation between the three types of colon
cancer cells, we measured the cell growth rates using
a colony formation assay. No significant difference in
the number of colonies was observed between the
cells treated with the DC-SIGNR protein and those
treated with control IgG (Additional file 4: Figure
S1A and B). Taken together, these data imply that
DC-SIGNR confers migration and invasion abilities on
colon cancer cells without altering the proliferation of
the cells.Mouse DC-SIGNR knockdown inhibits the liver metastatic
capacity of colon cancer cells in vivo
The above results indicate that DC-SIGNR enhances
colon cancer cell adhesion, migration and invasion. The
liver is the main site of DC-SIGNR production, and me-
tastasis to the liver is a characteristic step in the devel-
opment of colon cancer. Thus, we wanted to explore the
role of mouse DC-SIGNR in this process. It has been
demonstrated that plasmid DNA can be efficiently deliv-
ered to the liver by a hydrodynamic tail vein procedure,
which has allowed for the elucidation of the roles of
genes in disease development in animal models [28]. We
first injected two different mouse DC-SIGNR shRNA
plasmids and a control shRNA plasmid into the tail vein
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shRNAs was determined by RT-PCR and Western Blot
analysis after 3 days (Fig. 3a, b). Compared with the con-
trol shRNA, both of the DC-SIGNR shRNAs could re-
duce the expression of mouse DC-SIGNR. In addition,
mouse DC-SIGNR shRNA a was more efficient than
mouse DC-SIGNR shRNA b. Thus, we chose to useFig. 3 (See legend on next page.)mouse DC-SIGNR shRNA a for our subsequent studies.
We also studied the expression of mouse DC-SIGNR in
different organs after injection with the mouse DC-
SIGNR shRNA plasmid (Additional file 5: Figure S2A
and B). The results showed that the mouse DC-SIGNR
shRNA plasmid significantly decreased the expression of
mouse DC-SIGNR in the liver, whereas the gene
(See figure on previous page.)
Fig. 3 Mouse DC-SIGNR knockdown inhibits colon cancer liver metastasis in vivo. a, b The effects of two different mouse DC-SIGNR shRNA constructs
on the expression of mouse DC-SIGNR were detected by RT-PCR and Western Blot analysis. Liver tissue from mice injected with a non-targeting shRNA
plasmid was used as the positive control. β-actin was used as a loading control. c The effect of different doses of the mouse DC-SIGNR shRNA plasmid
on the expression of mouse DC-SIGNR was analysed by RT-PCR. The greyscale analysis of the mouse DC-SIGNR bands was normalized to β-actin.
d RT-PCR analysis was used to analyse the mouse DC-SIGNR expression in the mouse livers at the indicated time points following the injection of
60 μg of the mouse DC-SIGNR shRNA plasmid. The greyscale analysis of the mouse DC-SIGNR bands was normalized to β-actin. ***P < 0.001. e, f Liver
sections were extracted from mice 3 days after injection with the mDC-SIGNR shRNA plasmid or a control shRNA plasmid via tail vein. LoVo cells that
had adhered to frozen liver sections were detected by H&E staining. The adherent colon cancer cells are labelled with red arrows. g Representative
sections of liver tumors (n = 5 in each group). The black arrows indicate the tumor nodules. Knocking down mouse DC-SIGNR significantly decreased
the metastasis of LoVo and LS174T cells to the liver. h Comparison of the survival percentage of the mouse DC-SIGNR shRNA group and control shRNA
group. The survival percentage of mice in the mouse DC-SIGNR shRNA group was significantly higher than that of the control shRNA group for both
of the colon cancer cell lines (P = 0.0018 and P = 0.0027, respectively). i Haematoxylin and eosin (H&E)-stained liver and spleen sections are shown. Scale
bars, 50 μm and 100 μm, respectively. j The mean volume of tumors and the number of metastases in the liver were determined. k The mean volume
of tumors and the number of metastases in the spleen were determined. *P < 0.05, **P < 0.01, ***P < 0.001. The error bars in all graphs represent SD
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did not change after injection with the mouse DC-
SIGNR shRNA plasmid. We determined that the de-
creased expression of mouse DC-SIGNR could be de-
tected 3 days after the mouse DC-SIGNR shRNA
plasmid tail vein injection. The level of mouse DC-
SIGNR gene expression was dependent on the
amount of mouse DC-SIGNR shRNA plasmid that
was injected. Thus, we used different doses (10, 30,
50, and 60 μg) of the mouse DC-SIGNR shRNA plas-
mid for the tail vein injection experiment (Fig. 3c).
According to the results, injecting 60 μg of the mouse
DC-SIGNR shRNA plasmid per mouse was more effi-
cient than the other doses. Consequently, we chose
60 μg as the optimal dose of the mouse DC-SIGNR
shRNA plasmid for further study of the suppression
of mouse DC-SIGNR in the mouse liver. We evalu-
ated the expression of mouse DC-SIGNR over time
after the injection of 60 μg of the mouse DC-SIGNR
shRNA (Fig. 3d). The shRNA had an effect by the
third day after the tail vein injection, and on the fifth
and seventh days there was a distinct decrease in
mouse DC-SIGNR expression. However, on the tenth
day there was no statistical effect on the expression
of mouse DC-SIGNR. These results suggest that
60 μg of the mouse DC-SIGNR shRNA can signifi-
cantly decrease the expression of mouse DC-SIGNR
and that its effects may last for 10 days in vivo.
Next, we examined whether mDC-SIGNR could bind
to colon cancer cells. LoVo and LS174T colon cancer
cells were incubated with frozen liver sections that were
obtained from mice 3 days after treatment with either
60 μg of the mouse DC-SIGNR shRNA plasmid or with
the control shRNA plasmid by tail vein injection (Fig. 3e,
f ). The results showed that compared with the control
shRNA group, the adhesion of the colon cancer cells to
the mouse liver tissues that had been treated with mouse
DC-SIGNR shRNA was significantly decreased. These
data demonstrate that the knockdown of mouse DC-SIGNR affects the adhesion of human colon cancer cells
to liver tissues.
We then treated mice with 60 μg of the mouse DC-
SIGNR shRNA plasmid or a control shRNA plasmid via
tail vein injection. After 3 days, 5 × 106 LoVo or LS174T
cells were injected into the spleens of nude mice. The
mouse DC-SIGNR shRNA or control shRNA were re-
administered by tail vein injection every 10 days. The re-
sults showed that mouse DC-SIGNR shRNA signifi-
cantly attenuated the metastasis of both LoVo and
LS174T cells to the liver in comparison to the control
shRNA (Fig. 3g). In addition, the mouse DC-SIGNR
shRNA had no influence on the local growth of the
colon cancer cells. Kaplan-Meier survival curves were
generated to compare the condition of mice injected
with the two different cell lines and treated with either
the mouse DC-SIGNR or the control shRNA. We found
that for mice injected with LoVo cells, the survival per-
centage of mice in the mouse DC-SIGNR shRNA group
was significantly higher than in the control shRNA
group (Fig. 3h). The same results were obtained for mice
injected with LS174T cells. Moreover, we observed the
histological changes in the liver surrounding metastatic
foci by H&E staining, which revealed that knocking
down mouse DC-SIGNR significantly decreased the po-
tency of LoVo cell liver metastasis. However, there was
no difference in spleen tumors between the mouse DC-
SIGNR shRNA group and the control group (Fig. 3i).
Furthermore, we measured the mean tumour volumes in
each group and calculated the numbers of metastatic
foci in the liver and spleen (Fig. 3j, k). The tumor vol-
umes in the mouse DC-SIGNR shRNA group were
smaller, and the mice developed fewer micrometastatic
foci in liver tissue in the mouse DC-SIGNR shRNA ex-
perimental group compared with the control group.
However, the mouse DC-SIGNR shRNA plasmid did not
exert effects on the local growth of colon cancer cells.
These data imply that mouse DC-SIGNR knockdown in-
hibits colon cancer liver metastasis in vivo.
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The above findings demonstrate that mouse DC-SIGNR
is involved in colon cancer liver metastasis. However,
the role of human DC-SIGNR in this process has not
been studied. Thus, we also used hydrodynamicFig. 4 (See legend on next page.)injection to induce effective expression of exogenous hu-
man DC-SIGNR in mouse livers. The effect of the hu-
man DC-SIGNR expression plasmid was examined by
RT-PCR and Western Blot analysis after 1 day (Fig. 4a
and b). We found that human DC-SIGNR was expressed
(See figure on previous page.)
Fig. 4 Human DC-SIGNR is involved in colon cancer liver metastasis in vivo. a The impact of delivering a human DC-SIGNR expression plasmid to
mouse livers via tail vein injection was determined by RT-PCR analysis. Naked human DC-SIGNR plasmid DNA was used as a positive control.
β-actin served as a loading control. b The influence of the human DC-SIGNR expression plasmid was detected by a Western Blot assay. The re-
combinant DC-SIGNR protein acted as a positive control. c The human DC-SIGNR expression levels were observed after mice were treated with
different doses of the DC-SIGNR plasmid. The human DC-SIGNR levels were determined by RT-PCR (upper panel), and the relative expression of
DC-SIGNR was quantified from three triplicate experiments (lower panel). The greyscale analysis of the DC-SIGNR bands was normalized to β-actin
using Gelpro 32. d RT-PCR analysis of the human DC-SIGNR expression level in mice treated with 10 μg of the plasmid for the indicated lengths
of time. *P < 0.05, **P < 0.01 vs the 1 d group. e Liver tissues were taken from mice one day after injection with the DC-SIGNR plasmid or an
empty plasmid via tail vein. The adhesion of LoVo cells to frozen liver sections was detected by H&E staining. The red arrow marks the adherent
colon cancer cells. ***P < 0.001. f DC-SIGNR expression can significantly promote the adhesion of the three types of colon cancer cells to liver
tissues from mice treated with the DC-SIGNR expression plasmid by tail vein injection compared with the control group, and the interaction can
be inhibited by a DC-SIGNR antibody. The cells that had adhered to the liver tissues were counted. g Images showing representative tumors in
liver and spleen (n = 4 in each group). Human DC-SIGNR could increase the potency of liver metastasis in mice compared with an empty plasmid
but had no influence on the local tumor size. h Representative images of H&E and Ki67 staining of tumour tissues in liver and spleen are shown. i
The graph shows the mean volume of tumors and the number of metastases in the liver. j The volume of tumors and the number of metastatic
spleen foci was measured in each group. The error bars in all graphs represent SD
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man DC-SIGNR plasmid. We then injected different
doses of the human DC-SIGNR plasmid, and conse-
quently identified 10 μg as the optimal dose for human
DC-SIGNR expression (Fig. 4c). We injected mice with
10 μg of the human DC-SIGNR plasmid and observed
the gene expression in the liver over time. We found
that the human DC-SIGNR plasmid had obvious effects
on the first and second days after injection. However,
the gene expression was gradually attenuated, and on
the seventh day, we observed only faint DC-SIGNR ex-
pression in the liver tissues (Fig. 4d). These findings in-
dicate that human DC-SIGNR can be expressed in
mouse livers by human DC-SIGNR plasmid tail vein in-
jection and that its effect may last for 7 days.
In addition, we detected whether human DC-SIGNR
could adhere to liver tissue in mice. We incubated LoVo,
LS174T, and HCT-116 colon cancer cells with frozen
liver tissues from mice treated with the human DC-
SIGNR plasmid or an empty plasmid for 1 day. We
found that there were significantly more cells adhered to
the liver tissues from the DC-SIGNR plasmid group
compared with the control group, and the adhesive ac-
tions were inhibited by an anti-DC-SIGNR antibody
(1:500, Abcam, USA) (Fig. 4e, f ). These studies show
that the expression of human DC-SIGNR in mouse
livers induced by hydromechanical plasmid application
could feasibly attract colon cancer cells to adhere to the
liver tissue.
Thus, we have demonstrated that human DC-SIGR
could bind to liver tissue in mice, and it is necessary to
explore whether human DC-SIGNR is also related to
colon cancer liver metastasis. Nude mice were first ad-
ministered 10 μg of the human DC-SIGNR plasmid or
an empty plasmid by tail vein injection. After 1 day, 5 ×
106 LoVo, LS174T, or HCT-116 cells were injected into
the spleens of the mice. The injections of the human
DC-SIGNR plasmid or the empty plasmid were repeatedevery 7 days. Compared with the control groups, the
liver metastases volume was much larger in the mice
injected with the three colon cancer cell lines and
treated with the human DC-SIGNR plasmid (Fig. 4g). In
addition, there was no difference in the volume of the
spleen tumours between the human DC-SIGNR plasmid
group and the control group. Next, we observed the
histological changes in the liver surrounding metastatic
foci and local spleen tumours by H&E staining and im-
munohistochemical staining of Ki-67, CEA, CK20, and
CK7 (Fig. 4h; Additional file 5: Figure S2C). The H&E
staining of the metastases confirmed their homology
with the colon cancer cells, and there were more colon
cancer cells in the human DC-SIGNR plasmid group in
comparison to the empty plasmid group. Ki67 staining
indicated that more hyperproliferative Ki67+ tumour
cells were found in the liver tissue in the human DC-
SIGNR plasmid group compared with the control group.
Furthermore, we also measured the tumor volume and
counted the numbers of metastatic foci in the liver and
spleen for the groups injected with the different colon
cancer cell lines (Fig. 4i, j). Compared with the empty
plasmid group, the liver tumors grew much larger in the
human DC-SIGNR plasmid group. In addition, the hu-
man DC-SIGNR plasmid surprisingly induced more
micrometastatic liver foci compared to the empty plas-
mid. Additionally, in the mice injected with the three
cell lines, there were no differences in the tumor vol-
umes and the number of tumors per spleen between the
group treated with the human DC-SIGNR plasmid and
the group treated with the empty plasmid. In sum, these
data confirm that DC-SIGNR may participate in colon
cancer cell metastatic progression in the liver.
DC-SIGNR significantly induces the expression of
metallothioneins in colon cancer cells
To reveal the molecular alterations induced by DC-
SIGNR in colon cancer cells, we utilized the profiling
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Gene Expression Array. LoVo cells were incubated with
the DC-SIGNR protein or control IgG for 4 h. A total of
17,938 genes passed the filtering criteria and were fur-
ther analysed. Among these genes, only the expression
profiles of metallothionein family members (MT1M,
MT1B, MT1G, MT1H, MT1X, MT1F) could be readily
distinguished between DC-SIGNR protein-treated cells
and the control cells (Fig. 5a). Interestingly, there was no
difference in the genes related tumour metastasis, such
as MET, DRG1, or SMAD7 (Table 1). Notably, the aver-
age and median expression values of metallothioneins
were higher in the Fc-DC-SIGNR test group than in the
Fc-control group (Fig. 5b; Additional file 6: Table S1).
To validate the array results, semi-quantitative RT-PCRFig. 5 DC-SIGNR controls the expression of metallothioneins and MMP9. a Scat
4 h. The plot shows the different gene signal values between the two groups. T
were unchanged. b Hierarchical clustering of LoVo cells incubated with the DC-
genes (Q value ≤0.05 and fold change ≥2). The coloured lines of the dendrogram
level and red indicates a high relative level of gene expression. c Differential exp
LS174T) analysed using real-time PCR. The cells were treated with 5 μg/ml DC-S
expression of the genes was normalized to the GAPDH level. d The expression
or control IgG (4, 8, and 12 h) was detected by Western Blot. β-actin was used a
LoVo cells and LS174T cells that were incubated with the DC-SIGNR protein or c
expression of MMP9 in the two colon cancer cell lines treated with the DC-SIGN
metallothioneins was analysed by Western Blot in LoVo cells after infection with
and MMP9 were detected in LoVo cells after MMP9 knockdown by Western Blo
included three parts: molecular function, biological process and cellular compon
repeated three timesand Western Blot analysis were performed (Fig. 5c, d;
Additional file 7: Figure S3A and B). We detected the
expression of metallothioneins in LoVo and LS174T cells
incubated for different lengths of time with the DC-
SIGNR protein or control IgG. Consistent with the
microarray data, both cell lines treated with the DC-
SIGNR protein showed a more intense signal than the
control cells after 4 h of incubation. In addition, the ex-
pression of metallothioneins gradually decreased in a
time-dependent manner in the Fc-DC-SIGNR group.
Several studies have reported that metallothioneins are
capable of mediating MMP9 expression [29–31]. Our re-
sults have demonstrated that the DC-SIGNR protein
could significantly increase the expression of metal-
lothioneins after 4 h of incubation. Thus, we wanted toter plot of LoVo cells treated with the DC-SIGNR protein or control IgG for
he genes marked in red were upregulated, and the genes labelled in black
SIGNR protein or control IgG for 4 h, according to six differentially expressed
represent the support for each clustering. Green represents a low relative
ression of metallothioneins in two colon cancer cell lines (LoVo and
IGNR or control IgG in complete media for 4, 8, and 12 h. The mRNA
of metallothioneins in LoVo and LS174T cells treated with DC-SIGNR protein
s a control. e Real-time PCR was used to determine MMP9 expression in
ontrol IgG for 4 h and 8 h. f A Western Blot assay was used to detect the
R protein or control IgG for 4 and 8 h. g The expression of MMP9 and
lentiviral MT1M shRNA and control shRNA. h The levels of metallothioneins
t. i Gene Ontology analysis of metallothioneins and MMP9. The analysis
ent. The error bars in all graphs represent SD, and each experiment was
Table 1 Up-regulated and part of non-dysregulated genes by DC-SIGNR stimulated of LoVo cells
Affymetrix gene ID Fold change Q value Symbol Gene description
11728398_x_at 13.9704 0.0000 MT1M Metallothionein 1M
11730028_at 8.5857 0.0000 MT1B Metallothionein 1B
11717385_a_at 7.1304 0.0000 MT1G Metallothionein 1G
11731857_x_at 5.7220 0.0000 MT1H Metallothionein 1H
11757581_x_at 5.0677 0.0000 MT1X Metallothionein 1X
11721877_s_at 4.8745 0.0000 MT1F Metallothionein 1F
11723326_at 1.8636 0.0000 CA9 Carbonic anhydrase IX
11716408_a_at 1.025 39.5270 MET Met proto-oncogene
11763609_a_at 0.8917 124.9533 DRG1 Developmentally regulated GTP binding protein 1
11725514_a_at 0.9209 124.9533 SMAD7 SMAD family member 7
11734015_a_at 1.3274 39.5271 SMAD2 SMAD family member 2
11725363_s_at 1.1185 39.5271 SMAD4 SMAD family member 4
11721124_s_at 0.9999 124.9533 MMP11 Matrix metallopeptidase 11(stromelysin 3)
11725989_x_at 1.0338 39.5271 MMP14 Matrix metallopeptidase 14(membrane-inserted)
11727281_a_at 1.0732 39.5271 MMP28 Matrix metallopeptidase 28
11748126_a_at 1.2275 39.5271 TIMP2 TIMP metallopeptidase inhibitor 2
11724904_at 0.8562 124.9533 TIMP4 TIMP metallopeptidase inhibitor 4
11750190_x_at 1.0254 39.52701 CD44 CD44 molecule (Indian blood group)
11727668_a_at 0.9311 124.9533 MTA1 Metastasis associated 1
11758421_s_at 0.988 124.9533 PTEN Phosphatase and tensin homolog
11721226_x_at 1.1754 39.5271 MTSS1L Metastasis suppressor 1-like
11745021_a_at 0.8883 124.9533 MYC v-myc myelocytomatosis viral oncogene homolog (avian)
11728523_a_at 1.2524 39.5271 MYCL1 v-myc myelocytomatosis viral oncogene homolog
1, lung carcinoma derived (avian)
11727802_s_at 1.2701 39.5271 MYCBP c-myc binding protein
11717155_a_at 1.0641 39.5271 NME1 Non-metastatic cells 1, protein (NM23A) expressed
in NME1-NME2 readthrough
11718347_a_at 0.9329 124.9533 S100P S100 calcium binding protein P
11725371_s_at 0.9601 124.9533 VEGFA Vascular endothelial growth factor A
11758873_a_at 1.4568 39.5271 HPSE Heparanase
11754925_a_at 1.1226 39.5271 SYK Spleen tyrosine kinase
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Interestingly, we found that DC-SIGNR also increased
MMP9 expression in LoVo and LS174T cells after 4 h of
incubation, and this gene was not analysed by the gene
expression array (Fig. 5e, f ). Furthermore, we explored
the relationship between MMP9 and metallothioneins in
colon cancer cells. As a result, we found there was no
obvious change in MMP9 protein expression after
MT1M (which was upregulated most obviously of the
metallothioneins) knockdown in LoVo cells (Fig. 5g). Si-
lencing MMP9 significantly decreased the expression of
metallothioneins in LoVo cells as determined by West-
ern Blot analysis (Fig. 5h). In addition, we also reviewed
syndicated bioinformatics using the Molecule Annota-
tion System 3.0 and found that metallothioneins andMMP9 have many binding sites, are involved in many
biological processes, and are expressed mainly in the
cytoplasm (Fig. 5j). This evidence reveals that DC-
SIGNR regulates the expression of metallothioneins by
upregulating MMP9 during colon cancer liver
metastasis.
Increased levels of soluble DC-SIGNR were detected in
colon cancer patients with liver metastasis
Cell adhesion molecules are important mediators in the
process of tumor growth and metastasis. They are re-
leased into circulation or internalized rapidly under
shear conditions. In addition, increased serum levels of
adhesion molecules were reported to be correlated with
tumour metastasis [32]. In this study, we examined the
Fig. 6 Soluble DC-SIGNR is significantly upregulated in colon cancer pa-
tients with liver metastasis. The serum levels of DC-SIGNR were
detected by an enzyme-linked immunosorbent assay. a The scatter plot
shows the comparison of serum DC-SIGNR levels between patients with
stage III/IV colon cancer and healthy individuals. The level of serum
DC-SIGNR was significantly higher in patients with stage III/IV colon
cancer compared with healthy controls (P< 0.0001). b Comparison of
DC-SIGNR levels in colon cancer patients with liver metastasis and those
without metastasis. The serum DC-SIGNR level was statistically higher in
colon cancer patients with liver metastasis than those without metastasis
(P= 0.0258). The error bars in all graphs represent SD
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detect the relationship between soluble DC-SIGNR and
colon cancer liver metastasis. We investigated 138 par-
ticipants in total, and the serum levels of DC-SIGNR in
colon cancer patients (n = 81) and healthy controls (n =
57) were analysed by a standard sandwich ELISA
(Table 2). The results showed that serum DC-SIGNR
levels were significantly different between colon cancer
patients in stage III/IV (88.16 ± 51.78 ng/ml) and healthy
individuals (47.72 ± 24.94 ng/ml) (P < 0.0001) (Fig. 6a).
In addition, we detected that the serum concentrations
of DC-SIGNR were significantly higher in colon cancer
patients with liver metastasis (94.81 ± 44.99 ng/ml) than
in patients without metastasis (67.20 ± 29.67 ng/ml) (P =
0.0258) (Fig. 6b). These results validate that soluble DC-
SIGNR may be correlated with the process of colon can-
cer liver metastasis.
Discussion
In this study, we have demonstrated that DC-SIGNR
plays a functional role in promoting colon cancer metas-
tasis. Our results showed that the DC-SIGNR protein
dramatically induced colon cancer cell adhesion, migra-
tion and invasion properties in vitro. Mouse DC-SIGNR
and human DC-SIGNR are both involved in colon can-
cer liver metastasis in vivo. Furthermore, we showed that
DC-SIGNR promoted the liver metastasis of colon can-
cer cells through a novel regulatory pathway in which
DC-SIGNR notably increased the expression of metallo-
thionein isoforms and MMP9. Consistent with our ob-
servation, the serum levels of DC-SIGNR wereTable 2 Clinical data of the colon cancer patients in ELISA
study
Clinical data Cases Proportion sDC-SIGNR (ng/ml) median (range)
Gender
Female 32 39.51% 72.88 (33.46–245.0)
Male 49 60.49% 89.73 (26.81–249.3)
Age (year)
≧60 52 64.20% 62.25 (29.49–249.3)
<60 29 35.80% 74.76 (26.81–245.0)
Stage
I/II 20 24.69% 58.90 (29.49–140.0)
III/IV 61 75.31% 70.97 (26.81–249.3)
Type of cancer
Colon 42 51.85% 67.51 (33.83–249.3)
Rectal 39 48.15% 66.53 (26.81–202.2)
Metastatic site
No 20 24.69% 58.90 (29.49–140.0)
Liver 33 40.74% 86.26 (33.83–202.2)
Other 28 34.57% 59.71 (26.81–249.3)significantly higher in colon cancer patients with liver
metastasis than those without metastasis. In sum, we
have clearly demonstrated that DC-SIGNR is a critical
mediator of colon cancer liver metastasis.
Here, we have found that serum DC-SIGNR levels in
colon cancer patients with liver metastasis were higher
than in those without metastasis. Importantly, it is ne-
cessary to know whether colon cancer cells express DC-
SIGNR. We did not detect DC-SIGNR expression in the
three colon cancer cell lines used in this study by either
flow cytometry or Western Blot analysis (Additional file
8: Figure S4, A and B). In addition, our laboratory has
reported that immunohistochemical staining for DC-
SIGNR was negative in matched colon tissues and
tumour stroma and was only faintly positive between the
colon cancer foci [13]. Thus, we speculated that DC-
SIGNR, which is expressed in the liver, triggers colon
cancer cell adhesion, contributes to increased liver endo-
thelial cell permeability, and enables the transendothelial
migration and invasion of colon cancer cells (Fig. 7).
The expression of DC-SIGNR was increased and DC-
SIGNR was released into the bloodstream once colon
cancer cells appeared in the liver. This may explain the
upregulated serum levels of soluble DC-SIGNR in colon
cancer patients with liver metastasis.
DC-SIGNR is a trans-membrane protein, which com-
monly consist of three parts: extra-cellular, trans-
membrane, and intra-cellular domains. There is a neck
domain and a carbohydrate-recognition domain (CRD)
in the extra-cellular domain of DC-SIGNR. Reports have
shown that mouse DC-SIGNR has significant homology
to human DC-SIGNR in the CRD and transmembrane
domain [33]. Studies of the ligand binding properties in-
dicate that mouse DC-SIGNR interacts with a series of
fucosylated oligosaccharides (Lewisa, Lexwisb, Lewisx,
and Lewisy) and mannose structures as an adhesion
Fig. 7 Liver metastasis formation. Colon cancer cells detach from the primary sites, circulate in the surrounding tissues, and enter the blood
vessels (intravasation). The cells adhere to endothelial cells through the interaction between DC-SIGNR as a receptor on the surface of endothelial
cells and the receptor ligand expressed on colon cancer cells. DC-SIGNR increases the expression of MT1M, MT1B, MT1G, MT1H, MT1X, MT1F, and
MMP9 in colon cancer cells. Then, the cells are able to extravasate, migrate, invade into the nearby liver, and form the metastatic tumour
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human ICAM-2, which promotes lymphocyte migration
into the white pulp [34]. Moreover, mouse DC-SIGNR is
also abundantly expressed in the liver and lymph nodes,
similar to human DC-SIGNR. Thus, mouse DC-SIGNR
is very similar to human DC-SIGNR. We have demon-
strated that mouse DC-SIGNR was involved in colon
cancer liver metastasis, and down-regulating the expres-
sion of mouse DC-SIGNR could reduce the metastasis
of the tumour. However, considering both structure and
expression site, there is no single orthologue of DC-
SIGNR in mice that is strictly identical to human DC-
SIGNR. In contrast to the high similarity in the CRD re-
gion, the mouse DC-SIGNR has a much shorter neck
domain compared to human DC-SIGNR. There is a 191-
amino acid neck domain encoded by a single exon in
human DC-SIGNR. However, the mouse DC-SIGNR
neck domain has only 116 amino acids and is encoded
by four small exons [35]. This is probably a consequence
of a lesser degree of homology between mouse DC-
SIGNR and human DC-SIGNR. The expression of
mouse DC-SIGNR is similar but not identical to that of
human DC-SIGNR. Mouse DC-SIGNR is also expressed
by macrophages in the spleen marginal zone and lymph
node medulla and in the peritoneal cavity of BALB/C
mice [36]. It seems that mouse DC-SIGNR has attributes
of both human DC-SIGNR and DC-SIGN [37]. However,
mouse DC-SIGNR cannot completely replace human
DC-SIGNR. Thus, we also observed the role of human
DC-SIGNR in colon cancer liver metastasis. Conse-
quently, we found that human DC-SIGNR alsoparticipated in colon cancer liver metastasis and that in-
creasing the expression of human DC-SIGNR promoted
the occurrence of colon cancer liver metastasis.
Moreover, we also demonstrated that DC-SIGNR regu-
lates the expression of metallothioneins and MMP9. In-
creased expression of metallothioneins is a prognostic
indicator of poor survival for many cancers, such as gas-
tric cancer, non-small lung cancer, and breast cancer
[20, 38, 39]. In addition, metallothioneins are also re-
ported to correlate with tumour metastasis. In squamous
cell carcinoma of the oesophagus, metallothioneins
could predict lymph node status and distant metastasis
and were correlated with cell proliferation potential [40].
The overexpression of metallothioneins was statistically
more common in primary cutaneous malignant melan-
oma with haematogenous metastases, independent of
Breslow tumour thickness [41]. For colon cancer, the
overexpression of metallothioneins was a prognostic in-
dicator for the poor overall survival of patients with
colorectal cancer, independent of some main clinico-
pathological parameters [42]. To the best of our know-
ledge, this study is the first to analyse the expression
profiles of colon cancer cells treated with the DC-
SIGNR protein or control IgG using a microarray. Inter-
estingly, our data showed that metallothioneins (MT1M,
MT1B, MT1G, MT1H, MT1X, and MT1F) significantly
increased after 4 h of DC-SIGNR protein treatment and
then decreased in a time-dependent manner. Time-
course analyses of metallothionein expression have also
been reported by other researchers [43–45]. For ex-
ample, nickel significantly increased the transcript levels
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at 4 h after exposure, followed by a subsequent decrease
in expression [43]. Ren et al. demonstrated that
cadmium-induced metallothionein mRNA expression
was time-dependent in rats, showing that the mRNA ex-
pression levels were substantially increased after Cd
treatment, peaked at 3 h, and then declined. In addition,
the mRNA levels of metallothioneins in Sertoli cells
peaked at 6 h [44]. WAKIDA et al. found that MT-1
mRNA expression was significantly increased 6 h after a
middle cerebral artery occlusion and decreased at 12
and 24 h in the wild-type mouse brain [45].
In addition, several studies have reported the function
of metallothioneins in the regulation of MMP9 [29–31].
MMP9, a gene in the family of zinc-dependent enzymes
and capable of degrading various extracellular matrix
components, is associated with colon cancer liver metas-
tasis [46, 47]. Ondrej Zitka et al. [29] showed that the
activity of MMP9 was higher in the presence of metal-
lothioneins compared with an experimental collagen-
MMP9 mixture by chip-based gel electrophoresis, which
was similar to the temperature effect. Metallothionein-
2A, a member of the metallothioneins, could promote
breast cancer cell invasion by increasing the expression
level of MMP9. MT-2A activated the binding sites in the
MMP9 promoter region via modulating AP-1 and NF-
κB [30]. Another member, MT1E, could modulate the
motility and invasion of a human glioma cell line by up-
regulating MMP9 as well, and this interaction was also
related to an association between MT1E and NF-κB
[31]. In previous studies, possibly due to the high affinity
of metallothioneins for heavy metal zinc ions, it was
shown that metallothioneins can induce the activities of
zinc-dependent regulatory proteins, such as enzymes
and zinc-finger transcription factors. For MMP9, it may
be postulated that zinc ions present in the metallothio-
neins activate MMP9, which then degrades various
extracellular matrix proteins. Therefore, since we dem-
onstrated that the expression of metallothioneins in-
creased as a result of DC-SIGNR simulation, we also
wondered whether DC-SIGNR treatment had an effect
on MMP9 expression. Surprisingly, we found that the
expression of MMP9 was increased after 4 h of incuba-
tion with the DC-SIGNR protein and then decreased in
the next 4 h. Similar to metallothioneins, MMP9 de-
grades collagen with high efficiency and it is also
expressed in a time-dependent manner [48–50]. War-
ren’s findings indicated that uterine MMP9 increased in
response to oestrogen at 2–4 h and then decreased,
reaching basal levels at 8 h [48]. Gilet et al. reported that
aldosterone increased MMP9 mRNA levels in HL-60
cells after 1.5 h of incubation, and the MMP9 expression
peaked at 6 h, and then degraded by 24 h [49]. Zhang
et al. demonstrated that LPS triggers a rapid continuousincrease in MMP9 expression in blood samples during
1–3 h of incubation, but there was no MMP9 detected
after 3 h [50]. In our study, colon cancer cells flowed
into blood circulation and arrested the site of liver by
adhering to the sinusoidal cells. DC-SIGNR, which was
expressed in liver endothelial cells, increased the expres-
sions of metallothioneins and MMP9 in colon cancer
cells at 4 h with high activity.
Actually, cellular adhesion molecules play important
roles in tumor metastasis. The adhesive interaction of
specific adhesion molecules and receptors are the inter-
mediate procedures of the metastatic cascade. DC-
SIGNR, as it has a high affinity for ICAM-3, can capture
the mannose glycans present on HIV-1 gp120 and pro-
mote HIV-1 infection of T cells in trans [51]. DC-SIGNR
expressed in sinus endothelial cells was demonstrated to
form a continuous lining that mediated the binding to
ICAM-3 on T lymphocytes during their migration out of
the lymph nodes during an immune response [52]. Our
results showed that DC-SIGNR interacted with colon
cancer cells in a dose- and calcium-dependent manner.
Colon cancer cells exhibited a significantly and specific-
ally reduced adhesion to liver tissues that were extracted
from mice injected with the mouse DC-SIGNR shRNA
plasmid compared with tissues that were taken from
mice injected with the control shRNA plasmid. The
number of colon cancer cells adhering to liver tissues
was augmented when the mice were injected with a hu-
man DC-SIGNR expression plasmid. And the interaction
could be inhibited by the DC-SIGNR antibody which
acted on the tandem-repeated neck domain of DC-
SIGNR. For DC-SIGNR, the neck region is essential for
lectin tetramerization. This neck structure may consti-
tute a rigid neck support for the CRD and change the
angles and distances between the carbohydrate-binding
sites within the each constituent monomer. Thus, the
neck domain may have a significant impact on ligand
binding. Thus, these results provide the first experimen-
tal evidence to date linking colon cancer cell adhesion to
hepatic endothelial DC-SIGNR with the progression of
liver metastasis.
In addition, cell migration is also an essential factor in
tumour metastasis. In our study, we found that DC-
SIGNR increased the expression of metallothioneins and
MMP9. Metallothioneins are a family of cysteine-rich,
low molecular-weight proteins. In addition, their expres-
sion in the tumour plays an important role in cell migra-
tion and therefore influences the metastatic ability of
tumour. For example, Wu et al. reported that MT1E,
one of the metallothioneins, was considered to be im-
portant in bladder cancer cell migration and tumour
stage [53]. It has been demonstrated that metallthionein-
3 induces migration, proliferation, and invasion in triple-
negative breast cancer cells via the induction of
Na et al. Journal of Hematology & Oncology  (2017) 10:28 Page 16 of 18metalloproteinase expression [54]. Another key molecular
mediator of DC-SIGNR in colon cancer cells is MMP9.
MMP9 production and secretion by tumor cells are vital
factors involved in the promotion of metastasis. MMP9
can promote tumour progression by degrading the extra-
cellular matrix and facilitating cell migration, invasion and
metastasis [55]. In addition, silencing MMP9 expression
decreases cell migration and invasion and induces cell ag-
gregation [56, 57]. Our results also showed that MMP9
knockdown in LoVo cells could significantly decrease the
expression of metallothioneins; however, there was no dis-
tinct effect on MMP9 expression after MT1M silencing.
Thus, we concluded that DC-SIGNR, as an important
regulator, promoted colon cancer cell migration, invasion
and metastasis through the activation of metallothioneins
by upregulating MMP9 expression.
Conclusions
In summary, our study on DC-SIGNR indicates its novel
role in colon cancer liver metastasis. DC-SIGNR may be
a promising biomarker that provides a new therapeutic
strategy for the treatment of colon cancer.
Additional files
Additional file 1: Table S2. The table shows the clinical data of the
colon cancer patients in DC-SIGNR ELISA study. (DOCX 24 kb)
Additional file 2: Figure S5. The standard curve of soluble DC-SIGNR.
Human recombinant DC-SIGNR protein was for the standard sample and
linear regression was completed successfully, R2 = 0.9984. The OD value
and corresponding concentration of sDC-SIGNR were listed. (TIF 394 kb)
Additional file 3: Table S3. The table exhibits the primer sequences
used for quantitative real-time PCR. (DOCX 13 kb)
Additional file 4: Figure S1. DC-SIGNR did not promote colony forma-
tion in colon cancer cells. (A) The photographs indicated no influence of
DC-SIGNR protein on cell proliferation efficiency of LoVo cells. (B) The
histograms showed the clone cells number in respective cells.
(TIF 1926 kb)
Additional file 5: Figure S2. Mouse DC-SIGNR expression in different
organs and the tumor cells matched with colon cancer cells. (A-B) Mouse
DC-SIGNR expression in different organs via mouse DC-SIGNR shRNA and
control shRNA plasmid injection were detected by RT-PCR and Western
Blot. These results showed that the method of hydrodynamic injection of
mouse DC-SIGNR shRNA plasmid can significantly suppress mouse DC-
SIGNR expression in the liver. However, there was no obvious effect on
the mouse DC-SIGNR expression in spleen and lung. (C) Mice were
injected with LoVo cells into their spleens after human DC-SIGNR plasmid
tail vein injection. The liver and spleen tumor tissues were stained with
colon cancer markers CEA, CK20, and CK7. The tumors were positive for
CEA and CK20, and negative for CK7, which is a pattern exclusively in
colon cancer. ***P < 0.001. (TIF 2552 kb)
Additional file 6:Table S1. The table lists the gene expression profiling
data analyzed by human gene expression array. (XLS 4041 kb)
Additional file 7: Figure S3. DC-SIGNR could not regulate the
expressions of MET, DRG1 and SMAD7. (A-B) Colon cancer cells LoVo and
LS174T were treated with DC-SIGNR protein or control IgG for 4 h. No
differences in the expressions of MET, DRG1 and SMAD7 were detected
by quantitative real-time PCR. (TIF 217 kb)
Additional file 8: Figure S4. DC-SIGNR could not be expressed in
colon cancer cell lines. (A) The expression of DC-SIGNR was detected byflow cytometry. Results are presented as the percentage of three colon
cancer cells expressing DC-SIGNR. (B) Western Blot was used to test the
expression of DC-SIGNR in colon cancer cells. Recombinant DC-SIGNR
protein was used as positive control. (TIF 463 kb)
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